purpose make world smarter happier richer founded motley fool financial service company dedicated making world smarter happier richer motley fool reach million people every month premium investing solution free guidance market analysis foolcom toprated podcasts nonprofit motley fool foundation purpose make world smarter happier richer founded motley fool financial service company dedicated making world smarter happier richer motley fool reach million people every month premium investing solution free guidance market analysis foolcom toprated podcasts nonprofit motley fool foundation hrmy earnings call period ending december image source motley fool harmony bioscience hrmy q earnings callfeb etcontents prepared remark question answer call participant prepared remark operatorgood morning name brittany conference operator today time would like welcome everyone harmony bioscience fourth quarter full year financial result conference call participant line placed mute prevent background noise speaker remark questionandanswer session operator instruction please advised today conference may recorded operator instruction would like turn call luis sanay head investor relation please go aheadluis sanay head investor relation thank operator good morning everyone thank joining u today review harmony bioscience fourth quarter full year financial result provide business update start encourage everyone go investor section website find material accompany discussion today including reconciliation gaap nongaap financial measure stage life cycle believe nongaap financial result better represent underlying business performance speaker today call dr jeffrey dayno president ceo jeffrey dierks chief commercial officer dr kumar budur chief medical officer sandip kapadia chief financial officer chief administrative officeras reminder making forward looking statement today based current expectation belief statement subject certain risk uncertainty actual result may differ materially undertake obligation update statement even circumstance change encourage consult risk factor referenced sec filing additional detail would like turn call dr jeffrey dayno jeff jeff dayno president chief executive officer thank luis thanks everyone joining conference call today harmony continues growth story demonstrated team accomplishment throughout delivered another strong year performance across organization growing revenue average number patient wakix advanced clinical development program pitolisant moved next generation next gen formulation pitolisant clinic expanded pipeline diversified portfolio acquisition zynerba ongoing phase clinical trial patient fragile x syndrome yesterday announced fda granted priority review supplemental nda snda wakix pediatric narcolepsy pdufa date june st earlier week also shared fda granted orphan drug designation pitolisant treatment praderwilli syndrome pws preparing initiate pivotal phase tempo study patient pws age six reflects momentum across organization commercial business wakix narcolepsy clinical development program well positive interaction fda related program outcome also reflect excellence execution dedication team deliver strategy laid executing addition returned capital shareholder via share repurchase program continue take opportunistic approach program throughout year excited year ahead believe harmony poised accelerate growth fourth quarter reported wakix net revenue million full year net revenue million representing growth respectively result demonstrates significant underlying demand wakix durability brand going year five market factor drive confidence ability grow wakix include meaningfully differentiated product profile result broad clinical utility couple ability reach broad prescriber universe approximately hcps see treat almost diagnosed narcolepsy patient opportunity seen growth patient wakix prescribers every quarter since launch even entrance new branded generic oxybate treatment option coming market past year finally several investigational agent clinic narcolepsy see new novel mechanism action coming market impact growth wakix late life cycle polypharmacy market based reason along vast market opportunity remains narcolepsy believe continue grow franchise year come remain confident wakix represents billion plus opportunity adult narcolepsy alone well way evidenced net revenue guidance ranging million million addition strong commercial performance also advanced expanded clinical development enterprise several front kumar provide detail clinical development program later call first let highlight progress starting pediatric narcolepsy pleased fda granted priority review snda wakix expedites review process fda set pdufa date june st look forward collaborating agency potentially introduce new nonscheduled treatment option pediatric patient living narcolepsy turning idiopathic hypersomnia ih completing review full data set continue believe based totality data along pitolisant receiving orphan drug designation ih backdrop one currently approved product strong case made regarding overall benefit risk proposition pitolisant patient ih engaging agency goal mind meeting scheduled next month look forward working agency bringing potential new nonscheduled treatment option patient living ih current lifecycle management program pitolisant include ih praderwilli syndrome type myotonic dystrophy represent hundred thousand diagnosed patient u successful new indication could contribute additional billion revenue wakix franchise given pitolisants novel mechanism action success wakix market working next gen formulation pitolisant goal generate new ip extend pitolisant franchise beyond program entered clinic last quarter track report pk data first half year another key component growth strategy business development expand pipeline beyond wakix diversify portfolio beyond sleep wake zynerba acquisition closed last october represented important step direction excellent strategic fit harmony bringing two late stage development program focused orphan rare neuropsychiatric disorder significant unmet medical need stopping zynerba acquisition remain active business development continually assessing bd landscape focus rare neurological disease asset rare disease asset unmet medical need leverage existing infrastructure synergy across organization looking asset across range development stage preference late stage asset open early stage asset strategic fit approximately million cash cash equivalent investment year end solid financial position execute bd opportunity strategic priority u conclusion proud team accomplishment able help patient living narcolepsy advancing development program rare disease patient population experienced solid durable growth core commercial business strong momentum clinical development program expansion diversification pipeline asset based dedication commitment across organization excited opportunity remain focused developing commercializing innovative treatment patient living rare neurological disease unmet medical need turn call jeffrey dierks chief commercial officer provide detail commercial performance jeffjeff dierks chief commercial officer thank jeff strong year growth wakix year four commercialization adult narcolepsy fourth quarter represented strongest revenue quarter history continued growth momentum underlying business fundamental top line performance metric net revenue fourth quarter million representing growth quarter prior year second consecutive quarter million net revenue full year net revenue million increase full year continue see strong double digit growth net revenue wakix heading year five commercialization reflecting continued high interest wakix narcolepsy market solid performance continued growth reinforces long term belief wakix represents potential billion dollar plus opportunity adult narcolepsy alone would like share key highlight performance fourth quarter slide average number patient wakix fourth quarter increased approximately increase approximately average patient sequentially reported last quarter impressive growth average patient fourth quarter driven strong top line demand new patient start speaks continued product adoption importantly highlight remaining large diagnosed patient opportunity continue tap quarter market allows addition strong growth average number patient wakix also saw continued product adoption wakix narcolepsy healthcare community new existing prescribers number unique prescribers wakix increased fourth quarter importantly continue see growth product adoption wakix prescriber base beyond oxybate rem enrolled healthcare professional approximately healthcare professional enrolled oxybate rem program prescribed wakix todate reported last earnings call addition continued growth prescriber base also saw strong growth depth prescribing within approximately oxybate rem enrolled healthcare professional ability reach educate broad narcolepsy treating healthcare professional universe allow u access full diagnosed adult narcolepsy patient opportunity give u confidence continued growth wakix availability new generic oxybates impacted patient prescriber growth existing strong payer coverage wakix given meaningfully differentiated product profile wakix remains first fda approved treatment ed cataplexy narcolepsy scheduled controlled substance attribute continues appeal broader narcolepsy healthcare professional audience patient population driver brand growth summary another year strong commercial performance wakix full year net revenue million growth versus full year fourth quarter represented strongest revenue quarter harmony todate million net revenue average number patient wakix increased approximately wakix prescriber base within beyond oxybate rem enrolled healthcare professional audience continued grow lastly payer coverage remains strong even availability new engineered oxybate option wakix continues demonstrate durable growth narcolepsy market seen growth patient prescribers every quarter since launch even branded generic treatment availability new launch first four year market looking ahead expect continued growth underlying business fundamental wakix net revenue expected million million anticipate similar quarterly rhythm business experienced previous year traditional seasonal payer dynamic headwind impact entire industry whole q tailwind coming q q stronger prescription demand typical seasonal headwind q lower patient visit common product disease chronically managed tailwind fourth quarter close year new competition expected limited differentiation generic branded product near term pipeline coupled large remaining diagnosed patient opportunity unmet need polypharmacy nature narcolepsy market wakix well positioned continued growth ability educate broad rem nonrems narcolepsy treating healthcare professional audience ability tap full diagnosed patient opportunity give u confidence long term potential brand represent billion dollar plus opportunity adult narcolepsy alone commercial business resilient appreciate dedication impact entire commercial team passion narcolepsy patient community would like turn presentation kumar budur chief medical officer provide update clinical development pipeline kumarkumar budur chief medical officer thank jeff last year defining year harmony rd made great progress advancing expanding diversifying portfolio working nine different development program across five different asset several late stage development number also complexity program target broad set indication rare disease patient population significant unmet medical need grew portfolio also built strong experienced dedicated rd organization ready take new opportunity continue build existing portfolio new asset via business development proud work team every day look forward delivering potential new treatment option patient rare disease high unmet need full clinical development pipeline shown slide number starting pediatric narcolepsy submitted supplemental nda fda indication pediatric narcolepsy fourth quarter pleased fda decision grant priority review decision highlight need new treatment option approximately pediatric patient living narcolepsy fda set pdufa date june st look forward working fda potentially bring nonscheduled treatment option administered day morning pediatric patient narcolepsy moving development program idiopathic hypersomnia completed review full data set submitted fda meeting request fourth quarter discus path forward meeting scheduled march optimistic able find efficient path forward bring pitolisant patient idiopathic hypersomnia optimism based totality data strongly support pitolisants efficacy patient idiopathic hypersomnia especially context high unmet need one drug approved scheduled class iii controlled substance rem program label use class ii controlled stimulant significant safety issue data open label part study doubleblind randomized withdrawal part study ongoing long term extension study conjunction benign safety profile offer strong benefit proposition favor pitolisant patient idiopathic hypersomnia look forward engaging fda meeting scheduled next month making strong case positive benefit profile pitolisant idiopathic hypersomnia provide update ih program next earnings call praderwilli syndrome track initiate phase tempo study first quarter year global doubleblind randomized placebo controlled study randomize approximately patient either pitolisant placebo onetoone ratio duration doubleblind period treatment period week age range six year older primary endpoint change severity excessive daytime sleepiness measured promis sri tscore baseline end doubleblind treatment period compared placebo based promising data phase proofofconcept study also evaluating irritable disruptive behavior common pws phase registration study designed meet requirement indication pws also fulfill one two requirement gain pediatric exclusivity remain confident committed gain pediatric exclusivity wakix offer additional six month regulatory exclusivity back end modest package based discussion fda clear line sight requirement pwr include data pediatric narcolepsy patient data phase study pws making steady progress meet requirement pediatric narcolepsy snda submission fourth quarter initiation phase pws study quarter designed support effort gain pediatric exclusivity wakix myotonic dystrophy type dm pleased report positive top line result phase proofofconcept study saw clinically meaningful improvement excessive daytime sleepiness measured daytime sleepiness scale also fatigue assessed using fatigue severity scale data summarized slide important note two symptom excessive daytime sleepiness fatigue present approximately patient dm symptom impactful core symptom myelodonia progressive muscle weakness clear consistent dose response also demonstrated higher dose showing greater response lower dose across study endpoint addition safety profile patient population consistent established safety profile pitolisant currently reviewing complete data set ass opportunity inform next step noted past indication could pivotal next gen pitolisant based formulation much longer patent runway continue make good progress next gen pitolisant based formulation ng ng partner bioproject goal generating new ip extending pitolisant franchise beyond bringing new treatment option people living rare disease please note updated naming convention two formulation according respective market entry timing next gen ng modified formulation pitolisant potential clinical differentiation fast market strategy based demonstration bio equivalent expect launch ng within wakix life cycle next gen ng enhanced formulation pitolisant designed deliver optimal pk profile higher dosage strength formulation new ip full clinical development program expected launched toward end waix life cycle formulation ng ng entered clinic fourth quarter expect pk data first half year also pleased expand diversify pipeline last quarter acquisition zynerba brought zyn pharmaceutically produced synthetic cannabidiol devoid thc transdermal delivery like wakix represents another portfolio product opportunity currently enrolling patient pivotal phase reconnect trial fragile x syndrome excited opportunity approximately patient diagnosed fragile x syndrome u approved treatment significant unmet medical need opportunity ass timeline reconnect trial expect complete patient enrollment first quarter top line data mid zyn also studied open level phase proofofconcept study patient q deletion syndrome known inspire trial generated promising data represents another market opportunity approximately patient u interacting fda phase program q worth noting zyn global opportunity harmony look forward exploring exus opportunity bring novel treatment people living fragile x syndrome q around world conclude made great progress harmony advancing expanding diversifying portfolio resulting pipeline multiple late stage program look forward sharing additional update continue make progress clinical development program behalf harmony would like thank patient family participating clinical trial well clinical investigator site personnel effort commitment helping u advance development program turn call cfo sandip kapadia update financial performance sandipsandip kapadia chief financial officer thank kumar good morning everyone morning issued fourth quarter earnings release filed k find detail fourth quarter full year financial operating result financial performance also shown slide finished year strong momentum across business helping u deliver solid growth across several key metric reported million annual wakix net revenue achieved third year profitability along robust cash generation addition advanced pitolisant life cycle management program executed business development acquisition zynerba also deployed capital toward share repurchase program overall remain well positioned execute growth strategy moving forward let take moment review financial result detail fourth quarter reported strongest revenue quarter company history net revenue million compared million prior year quarter representing growth performance quarter reflects strong continued underlying demand wakix fourth quarter operating expense million compared million prior year quarter higher operating expense primarily driven advancement clinical development program including zyn expense related commercialization wakix onetime zynerba transaction related cost million operating income fourth quarter million compared million prior year quarter nongaap adjusted net income fourth quarter million per diluted share compared million per diluted share prior year quarter believe nongaap adjusted net income better reflects underlying business performance please refer press release reconciliation gaap nongaap result ended year million cash cash equivalent investment security balance sheet balance reflects continued strong cash generation approximately million cash operation fourth quarter offset zynerba acquisition cost share repurchase activity quarter full year generated million cash operation fourth quarter returned capital shareholder repurchased approximately million share common stock million bringing full year total repurchase activity million share common stock million moving forward expect continue opportunistically repurchase share remaining share repurchase program authorization million strong balance sheet allows u execute return capital also maintain financial flexibility execute business development fourth quarter closed acquisition zynerba treated asset acquisition accounting purpose previously disclosed paid approximately million cash closing transaction received approximately million cash million deferred tax asset acquisition assumed approximately million liability thus recorded million ip rd charge related acquisition along million onetime restructuring cost result able acquire two late stage program attractive deal term going forward recognize considerable operating synergy expect ongoing incremental cost zynerba development program approximately million turning guidance full year expect net revenue million million range reflects thoughtful balanced approach providing guidance first time company history also highlight well way toward billion plus opportunity adult narcolepsy alone consistently communicated remain confident finally comment seasonality think phasing revenue first quarter expect see typical seasonal dynamic industry whole experience year q higher gross net deduction due insurance plan reset higher copay obligation along drawdown trade inventory conclusion pleased strong financial performance remain well positioned continue growth beyond look forward leveraging financial strength continue expand diversify portfolio also returning capital shareholder share repurchase program would like turn call back jeff closing remark jeffjeff dayno president chief executive officer thank sandip summary harmony continues growth story evidenced significant progress team made looking ahead see durability core business strong momentum development program remain focused continuing grow wakix business helping even adult patient living narcolepsy advancing pipeline across pitolisant zyn clinical development program working partner bioproject next gen formulation extend pitolisant franchise help even patient living rare neurological disease continuing build pipeline business development create robust portfolio rare disease asset covering stage development deploying capital maximize shareholder value share repurchase program business development opportunity excited come year believe poised accelerate harmony growth concludes planned remark today thank joining call turn call back operator facilitate qa session operator please open call question question answer operatoroperator instruction take first question ami fadia needham company line openami fadia needham company analyst good morning thanks taking question thank giving update pipeline firstly two question first talk two new pitolisant formulation going sharing data first half expect see data set expectation investor able get visibility formulation may differentiated wakix based data second question regarding idiopathic hypersomnia could share additional color analysis put together meeting fda could comment whether possibility generating additional data openlabel portion study support approvaljeff dayno president chief executive officer ask kumar comment next gen formulation visibility well preparation fda meeting ih kumarkumar budur chief medical officer term next gen formulation mentioned made significant progress next gen formulation last year really pleased bring two formulation clinic fourth quarter previously said provide data next gen formulation first half year term next gen ng modified pitolisant formulation potential clinical differentiation first market strategy demonstrating bioequivalence alongside clinical study offer meaningful clinical differentiation patient nature clinical study potential differentiation offered discussed next earnings call along pk data next gen ng formulation enhanced formulation pitolisant designed deliver optimized pk also ability go higher dose strength formulation full development program new ip extend pitolisant franchise well beyond plan provide pk data formulation next earnings call regarding question idiopathic hypersomnia ami totality data openlabel study randomized withdrawal period study long term extension study support pitolisants efficacy patient idiopathic hyperphromia term argument discussion fda totality data nonscheduled startup pitolisant ease administration relatively benign safety profile especially context one drug happens schedule iii controlled substance label use class ii controlled substance drug safety profile factor offer strong benefit risk proposition bring pitolisant patient idiopathic hyperphromia hope good discussion fda find efficient path forward bring pitolisant patient idiopathic hyperphromia soon possibleami fadia needham company analyst thank youoperatorthank take next question charles duncan cantor fitzgerald line opencharles duncan cantor fitzgerald analyst hey good morning jeff team congratulation good year thanks taking question one commercial question pipeline question follow regarding commercial question absolutely appreciate rev guide look good note added patient wakix per quarter last three quarter seems really consistent number guess wondering could speak anything market dynamic prescriber access result serendipityjeff dayno president chief executive officer think know jeff dierks provide color patient add continued market opportunity wakixjeff dierks chief commercial officer extremely pleased durable growth seen average number patient wakix think thing seeing charles given unique meaningfully differentiated product profile wakix ability sale team ability engage broad approximate healthcare professional see treat narcolepsy patient affords u opportunity tap full diagnosed patient opportunity individual healthcare professional outside oxybate rem program continue see meaningful growth number unique writer every quarter even within oxybate rem enrolled healthcare professional even availability generic nightly oxybate launch year seeing meaningful growth term depth prescribing audience think really seeing unique nature meaningfully differentiated product profile nonscheduled status broad clinical utility jeff dayno spoke really affords u ability continue tap broad diagnosed patient opportunity market allows around traditional quarterly dynamic speak earnings call charles extremely pleased seeing hearing well confident continued growth average number patient move charles duncan cantor fitzgerald analyst quick question pipeline actually multipart question sorry appreciate phase tempo study data data detail wondering would anticipate data rapidly think study enroll given competing program nda snda timing assume would gated open label extension would file perhaps completed second part question regarding pediatric narcolepsy priority review seems say something agency perspective safety product wondering could provide thought recent priority review grantedjeff dayno president chief executive officer charles first let say think excited initiating phase tempo study patient praderwilli kumar comment circle back thought priority review pediatric narcolepsy snda kumarkumar budur chief medical officer regarding pws study first pleased orphan drug designation fda pws program term recruitment anticipate complete enrollment two year true charles multiple program space one looking excessive daytime sleepiness behavioral symptom pws program targeting toward hyperphagia pws mentioned previously half patient pws excessive daytime sleepiness almost patient behavioral disturbance proofofconcept study showed strong data supporting pitolisants efficacy excessive daytime sleepiness inaudiblejeff dayno president chief executive officer charles repeat second question pediatric narcolepsy sndacharles duncan cantor fitzgerald analyst pediatric narcolepsy pdufa rapid time respond seems say something safety product agency perspective speaking agency course combined priority review guess thought perspective thatjeff dayno president chief executive officer charles mean would say think shared week pleased interaction fda regard orphan drug designation pitolisant praderwilli followed decision priority review pediatric narcolepsy snda think reflects regard overall benefit risk profile pitolisant said along advancing development program concern regard safety profile consistent original pivotal development program narcolepsy life cycle management program conducting real change overall safety profile favorable benefit risk profile think reflects positive interaction agency decision received remain focused execution advancement development program bring potential new treatment option patient populationscharles duncan cantor fitzgerald analyst good thanks added info congrats good yearjeff dayno president chief executive officer thanks charlesoperatorthank take next question francois brisebois oppenheimer line openfrancois brisebois oppenheimer company analyst hi thanks taking question wondering term guidance help u understand thought process behind giving guidance first time thinking revenue patient thank youjeff dayno president chief executive officer sandipsandip kapadia chief financial officer mean guidance represents would say thoughtful balanced approach especially first year given guidance think certainly look opportunity provide update go throughout year respect guidancefrancois brisebois oppenheimer company analyst think pricing maybe revenue per patient –sandip kapadia chief financial officer think take price increase earlier year good portion usually follows bottom line think generally see impact go throughout year obviously first quarter usually headwind regarding grosstonet pressure normal thing happen typically seasonality happened generally see much first quarter generally go throughout year see benefit similar pattern last three four yearsfrancois brisebois oppenheimer company analyst great thank muchjeff dayno president chief executive officer thanks francoperatorthank take next question david amsellem piper sandler line opendavid amsellem piper sandler analyst yeah thanks couple first regarding business development wanted get detailed thought extent larger scale transaction versus something smaller scale along line zynerba philosophically thinking acquisition general tied question also would lever lever significantly something wanted pick brain orexins seen data takeda alkermes others course wanted get view potential long term impact orexin receptor agonist extent one reach marketjeff dayno president chief executive officer think regard business development assessing landscape actively open sort opportunity regard deal similar zynerba good strategic fit well something transformational strong sort financial position transact first looked good strategic fit prefer sort late stage asset open earlier stage could launch wakix life cycle term capacity ask sandip comment thatsandip kapadia chief financial officer good financial strength flexibility execute business development also access debt appropriate well capital market also mentioned million cash cash equivalent available generating significant positive cash flow last quarter million cash flow generation well almost million last year cash generation think good flexibility jeff mentioned look small addon transaction well potentially something larger transformative think important thing filter jeff mentioned upfront term making sure good strategic fit company think capital perspective broad flexibilityjeff dayno president chief executive officer david turning question orexin agonist mean know space well following closely obviously lot attention lately given data come think high level program still early obviously advancing think question generated safety side efficacy side based data coming obviously target interesting term next potential novel mechanism action narcolepsy central disorder hypersomnolence think following space closely data come question generated think likely come market successful toward end decade toward end wakix life cycle importantly belief narcolepsy continue polypharmacy market new entrant help space share voice education interesting novel target think way seen development program advance continue polypharmacy market follow thing go forwarddavid amsellem piper sandler analyst right thanksjeff dayno president chief executive officer thanks davidoperatorthank take next question jason gerberry bank america line openunknown speaker hey guy thanks taking question bhavan jason first question regard zygel asset enrollment phase fragile x syndrome study added clarity assumption shape view mid readout timing second commercial question assumption average revenue per wakix patient meaningful tailwind revenue growth guidance growth mainly driven volumejeff dayno president chief executive officer ask kumar comment zyn phase reconnect trial exciting opportunity u provide kind color therekumar budur chief medical officer looked timeline mentioned previously based historical recruitment plan anticipated recruitment particular patient population arrived complete enrollment first quarter top line mid asset within half obviously bring additional resource expertise clinical development perspective also advocacy group perspective well try accelerate recruitmentjeff dayno president chief executive officer term revenue per patient jeff dierks want comment thatjeff dierks chief commercial officer looking ahead question term price volume average revenue per patient sandip shared took price increase beginning year previous year would expect capture price increase looking guidance right could see expecting plus percent growth could see vast majority growth expecting driven volume talked lot large remaining diagnosed patient opportunity meaningfully differentiated product profile wakix see significant opportunity room growth hopefully provides little bit context help think price versus volume assumption average revenue per patient unknown speaker could one followup question appetite share buyback look like relative million share buyback guy jeff dayno president chief executive officer think said looking take opportunistic approach sandip want comment furthersandip kapadia chief financial officer pleased last year able approximately million share repurchase activity last couple quarter think really question either flexibility respect business development obviously talked strategy term share buyback would look opportunistically appropriate level would certainly great cash position able execute approximately million capacity still remainingunknown speaker thank youoperatorthank take next question danielle brill raymond james line opendanielle brill raymond james analyst hi guy good morning thanks question also hoping could provide color assumption went guidance specifically around expectation patient add look like expecting slowdown net patient add quarter conservative growth starting moderate follow remind u impact label expansion pediatric narcolepsy population overall tam wakixjeff dayno president chief executive officer regard think term revenue revenue guidance sandip want sandip kapadia chief financial officer think mentioned taken thoughtful balanced approach term providing guidance first year certainly look provide update go throughout year way indicating see great momentum coming fourth quarter expect momentum sort carry year mean jeff dierks want comment term overall growth seeingjeff dierks chief commercial officer danielle term looking average patient growth sort assumption guidance mean seen seen demonstrated durable growth narcolepsy market grown average patient every quarter since launch even availability within durable growth growth evolved every year entering year five orphan launch going expect growth continue evolve follow previous year cadence quarterly growth tap large diagnosed patient opportunity see traditional payer headwind first quarter impact brand specialty product see traditional fewer patient visit associated chronically managed condition disease q typically previous year expect traditional tailwind second fourth quarter stronger prescription demand think though takeaway extremely pleased seeing confident continued growth really believe wakix well positioned future growth jeff dayno president chief executive officer next question –sandip kapadia chief financial officer pediatric tam expands wakix opportunity –jeff dayno president chief executive officer think jeff speak think obviously positive signal agency importance indication pediatric narcolepsy patient jeff opportunity look likejeff dierks chief commercial officer mean danielle estimate pediatric narcolepsy patient u although large opportunity important one underserved patient population one fda approved treatment option sodium oxybate schedule iii rem product right think excited potential successful bring nonscheduled treatment option given seen impact narcolepsy individual livesjeff dayno president chief executive officer danielle let also add regard pediatric narcolepsy snda also important data also pursuing pediatric exclusivity obviously important commercial opportunity regard additional six month regulatory exclusivity data one component along data generating phase praderwilli tempo study component important advancing making progress term pediatric narcolepsy data submission initiation phase trial praderwilli syndrome component sort would required pursue pediatric exclusivity additional six month protectiondanielle brill raymond james analyst ok thank muchjeff dayno president chief executive officer thanks danielleoperatorthank take next question graig suvannavejh mizuho line openunknown speaker hi avantika graig question one fragile x opportunity know said time line pushed little bit due enrollment change trial design originally also caused delay also pediatric opportunity know said pretty small opportunity anticipate growing wakix sale force approvedjeff dayno president chief executive officer regard fragile x study kumarkumar budur chief medical officer fragile x syndrome time line pushed mentioned evaluate time line asset house opportunity evaluate time line based historical recruitment plan anticipated recruitment patient population arrived completing enrollment first quarter top line anticipated wake mid change study designjeff dayno president chief executive officer would add think opportunity harmony u put resource toward driving phase reconnect trial forward regard experience clinical development team capacity operational perspective really engaging patient community patient advocacy effort well drive forward toward significant market opportunity diagnosed patient u turning pediatric narcolepsy keep sort small market opportunity important one think jeff sort alluded important one term potential new nonscheduled treatment option pediatric patient narcolepsy rather schedule ii stimulant looking forward working agency toward regard impact market opportunity jeffjeff dierks chief commercial officer looking sale force coverage pediatric narcolepsy believe optimized narcolepsy opportunity existing sale force footprint new prescribers adding target list successful believe current team excited potential bring forward optimized able take new opportunity additional patient addition handful healthcare professional high overlap adult narcolepsy prescribing pediatric narcolepsy prescribing believe got relationship established good portion prescribers absolutely optimized team successful excited bring new indication forwardunknown speaker squeeze one gross net know said headwind first quarter quantify think full yearjeff dayno president chief executive officer sandipsandip kapadia chief financial officer mentioned typically first quarter across industry general headwind higher copay obligation insurance plan reset first quarter see couple percentage point impact typically seen past first quarter sort improved go throughout year generallyunknown speaker thank youoperatorthank showing question would like turn call back management closing remarksjeff dayno president chief executive officer thank brittany thanks everyone joining call today interest harmony heard u morning strong execution solid momentum going year position harmony well continued growth look forward providing update execute growth strategy thank great dayoperatoroperator signoff duration minutescall participantsluis sanay head investor relationsjeff dayno president chief executive officerjeff dierks chief commercial officerkumar budur chief medical officersandip kapadia chief financial officerami fadia needham company analystcharles duncan cantor fitzgerald analystfrancois brisebois oppenheimer company analystdavid amsellem piper sandler analystunknown speakerdanielle brill raymond james analyst hrmy analysis earnings call transcript article transcript conference call produced motley fool strive foolish best may error omission inaccuracy transcript article motley fool assume responsibility use content strongly encourage research including listening call reading company sec filing please see term condition additional detail including obligatory capitalized disclaimer liabilitythe motley fool position stock mentioned motley fool disclosure policy